Suppr超能文献

经皮二尖瓣修复术使用MitraClip治疗合并与不合并心房颤动患者的结局比较

Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation.

作者信息

Velu Juliëtte F, Kortlandt Friso A, Hendriks Tom, Schurer Remco A J, van Boven Ad J, Koch Karel T, Vis M Marije, Henriques Jose P, Piek Jan J, Van den Branden Ben J L, Schaap Jeroen, Rensing Benno J, Swaans Martin J, Bouma Berto J, Van der Heyden Jan A S, Baan Jan

机构信息

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.

Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.

出版信息

Am J Cardiol. 2017 Dec 1;120(11):2035-2040. doi: 10.1016/j.amjcard.2017.08.022. Epub 2017 Aug 30.

Abstract

Percutaneous mitral valve repair with the MitraClip is an established treatment for patients with mitral regurgitation (MR) who are inoperable or at high risk for surgery. Atrial Fibrillation (AF) frequently coincides with MR, but only scarce data of the influence of AF on outcome after MitraClip is available. The aim of the current study was to compare the clinical outcome after MitraClip treatment in patients with versus without atrial fibrillation. Between January 2009 and January 2016, all consecutive patients treated with a MitraClip in 5 Dutch centers were included. Outcome measures were survival, symptoms, MR grade, and stroke incidence. In total, 618 patients were treated with a MitraClip. Patients with AF were older, had higher N-terminal B-type natriuretic peptide levels, more tricuspid regurgitation, less often coronary artery disease and a better left ventricular function. Survival of patients treated with the MitraClip was similar for patients with AF (82%) and without AF (non-AF; 85%) after 1 year (p = 0.30), but significantly different after 5-year follow-up (AF 34%; non-AF 47%; p = 0.006). After 1 month, 64% of the patients with AF were in New York Heart Association class I or II, in contrast to 77% of the patients without AF (p = 0.001). The stroke incidence appeared not to be significantly different (AF 1.8%; non-AF 1.0%; p = 0.40). In conclusion, patients with AF had similar 1-year survival, MR reduction, and stroke incidence compared with non-AF patients. However, MitraClip patients with AF had reduced long-term survival and remained more symptomatic compared with those without AF.

摘要

使用MitraClip进行经皮二尖瓣修复术是治疗无法手术或手术风险高的二尖瓣反流(MR)患者的既定疗法。心房颤动(AF)常与MR同时出现,但关于AF对MitraClip术后结局影响的数据却很少。本研究的目的是比较接受MitraClip治疗的有房颤和无房颤患者的临床结局。2009年1月至2016年1月期间,纳入了荷兰5个中心所有连续接受MitraClip治疗的患者。结局指标包括生存率、症状、MR分级和中风发生率。共有618例患者接受了MitraClip治疗。有AF的患者年龄更大,N末端B型利钠肽水平更高,三尖瓣反流更多,冠心病较少见,左心室功能更好。接受MitraClip治疗的患者,房颤患者1年后的生存率(82%)与无房颤患者(非房颤;85%)相似(p = 0.30),但5年随访后有显著差异(房颤34%;非房颤47%;p = 0.006)。1个月后,64%的房颤患者纽约心脏协会心功能分级为I或II级,而无房颤患者为77%(p = 0.001)。中风发生率似乎没有显著差异(房颤1.8%;非房颤1.0%;p = 0.40)。总之,与非房颤患者相比,房颤患者1年生存率、MR降低程度和中风发生率相似。然而,与无房颤的MitraClip患者相比,有房颤的患者长期生存率降低,症状更明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验